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Introduction. Cytomegalovirus (CMV) is a linear double-stranded DNA virus that may cause severe and potentially fatal infection
in immunocompromised hosts. In immunocompetent individuals, the infection is typically mild or asymptomatic. However, in
the last years, some cases of severe cytomegalovirus infection in immunocompetent individuals have been described. Clinical
Presentation. 'e authors present a male patient aged 42 years, without specific medical history, who presented a 15-day history of
fever, headache, night sweats, odynophagia, and bilateral otalgia, without improvement after four days of therapy with
amoxicillin/clavulanic acid. Blood count and biochemistry were performed with liver cytolysis pattern. Chest teleradiography
showed diffuse interstitial infiltrate. 'oracic CT scan revealed areas in a ground glass with a cross-linking component in the left
and right upper lung lobes compatible with an inflammatory/infectious process. Blood serology was positive for CMV IgG and
IgM. 'e detection on blood and bronchoalveolar lavage of CMV DNA by polymerase chain reaction (PCR) was also positive.
Ganciclovir was started based on the clinical features and the result of CMV serology. After 48 hours, there was a significant
clinical improvement, with remission of fever, and he was discharged on the 13th day of hospitalization with oral valganciclovir,
completing a 21-day antiviral course at home. Conclusion. With this clinical case, the authors highlight the importance of
considering CMV infection in evaluating patients with pneumonia, even in immunocompetent ones, particularly in those with no
clinical improvement with antibiotics instituted for bacterial pneumonia, and when other causes have been ruled out.
1. Introduction
Cytomegalovirus is a DNA virus belonging to the Herpesviridae
family with a high serological prevalence in healthy adults (50 to
90%) [1], and in Portugal, it is about 77% [2]. It is transmitted by
contact with infected body fluids or via the transplacental route
[2, 3] and is often acquired in childhood or early adolescence [4].
'e spectrum of diseases caused by CMV is diverse,
depending fundamentally on the host. In immunocom-
promised hosts, infection by this agent causes significant
morbidity and mortality, especially in transplant recipi-
ents and in those infected with the human immunode-
ficiency virus (HIV) [5, 6]. In the immunocompetent host,
the infection is usually asymptomatic or can present as a
mononucleosis-like syndrome [2, 4]. Some patients may
experience prolonged fever for 2 to 3 weeks [2, 7].
Symptomatic infection involving the respiratory system
appears to be rare (about 8%) [2, 8], presenting, usually,
with respiratory failure and with interstitial infiltrate on
chest X-ray [2]. 'e diagnosis is confirmed by serological
testing (detection of CMV-specific immunoglobulin (Ig)
M or a four-fold increase in CMV-specific IgG), molecular
biology, and histological findings in lung biopsy [2].
Although ganciclovir or valganciclovir are currently
recommended as first-line pharmacological agents in the
treatment of immunocompromised patients with severe
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disease, there are still uncertainties regarding these agents’
role in immunocompetent patients [4, 9].
2. Patient Information
A 42-year-old Caucasianmale patient with no relevant medical
history and no usual medication went to his attending phy-
sician for remitting fever (tympanic temperature (TT) maxi-
mum 38.9°C) associated with night sweats, odynophagia, and
bilateral otalgia, with 15 days of evolution. He was medicated
empirically with amoxicillin/clavulanic acid and paracetamol.
Four days later, he went to the emergency department (ER)
due to the persistence of fever and the onset of nausea, asthenia,
and intermittent occipital headache, intensity 8 out of 10
(numerical scale of pain), with irradiation to the frontal region,
photo and sonophobia, and partial pain relief with paracetamol.
3. Clinical Findings
Upon observation, he was pale, had fever (TT 38°C), nor-
motensive, and tachycardiac (115 bpm), with a respiratory
frequency of 18 breaths/min and 98% of peripheral oxygen
saturation. Cardiac and pulmonary auscultation did not
reveal changes. 'e oropharynx had hyperemia and aph-
thous stomatitis. Otoscopy showed hyperemia of both
tympanic membranes. Meningeal signs were negative.
4. Diagnostic Assessment
Performed blood count and biochemistry showed liver profile
with liver cytolysis pattern –207U/L aspartate aminotrans-
ferase (AST) and 125U/L alanine aminotransferase (ALT);
692U/L lactic dehydrogenase; normochromic anemia;
ionogram and renal function without changes; C-reactive
protein (CRP) 22.33mg/L. No pulmonary or pleural in-
volvement on chest X-ray. Cranial brain computed tomog-
raphy (CT) showed no ischemic or hemorrhagic changes. He
underwent a SARS-CoV-2 CRP test which was negative. We
searched for hepatitis A antibody, hepatitis B surface antigen,
and hepatitis C antibody, which were negative. Active in-
fection by herpes simplex virus (HSV) 1 and 2 (IgM anti-HSV
1 and IgM anti-HSV 2< 0.8), influenza A and B, respiratory
syncytial virus (RSV), HIV 1 and 2, and Epstein–Barr (viral
capsid antigen (VCA) IgG, VCA IgM, and Epstein–Barr
nuclear antigen (EBNA) negatives) were also excluded. En-
terovirus and parvovirus B19 infection were also excluded as
well as leptospira infection. A therapeutic adjustment was
performed with oseltamivir and ibuprofen.
Due to persistent fever and headache, he went to the ER
again three days later. On admission, he reported dyspnea for
medium exertion, intermittent chest pain, grade 6 out of 10,
without irradiation and unrelated to body movements, and dry
cough. On physical examination, he was subfebrile (TT 37.8°C)
but hemodynamically stable. He maintained aphthous stoma-
titis and hyperemia of the oropharynx and tympanic mem-
branes. Analytically, the maintenance of the pattern of liver
cytolysis and elevation of CRP (46.52mg/L) is highlighted
(Table 1). Peripheral blood smear with 16%
activated lymphocytes and normochromic normocytic anemia.
'e patient was admitted to the Department of Internal
Medicine, and the respective etiological study of the fever
was carried out in the context of hospitalization. Blood and
urine cultures were negative for bacteria and fungi. Coxiella
burnetii and Mycoplasma pneumoniae antibodies’ assays
were negative. Urinary antigens for Legionella and Strep-
tococcus pneumoniae were negative. Other serologies were
negative: Chlamydophila pneumoniae, Toxoplasma gondii,
and VDRL. 'e lumbar puncture excluded infection of the
central nervous system. We searched for autoimmune dis-
eases (lupus anticoagulant, anticardiolipin antibodies, an-
tinuclear antibodies, anti-smooth muscle antibodies, and
anti-double-strand DNA antibodies) but were negative.
From the imaging study carried out, bilateral perihilar
reinforcement, erasure of the costophrenic sinuses, and
diffuse interstitial infiltrate were found in chest tele-
radiography (Figure 1). 'oracic-abdominal-pelvic CT
showed areas in a ground glass with a cross-linking com-
ponent in the left and right upper lung lobes compatible with
an inflammatory/infectious process (Figure 2). It also
revealed the presence of bilateral pleural effusion, hepato-
megaly with periportal and perihepatic edema, spleno-
megaly, and free fluid in a right paritetocolic drip. A
transthoracic echocardiogram was performed showing no
abnormal changes.
Initially, since the patient was considered immuno-
competent, CMV serology was not requested. However, and
after excluding all possible etiologies, they were researched.
Alterations compatible with CMV primoinfection were
detected—anti-CMV IgM antibodies 6.91 S/CO and anti-
CMV IgG 21.4 UA/mL. 'e detection on blood of CMV
DNA by real-time quantitative polymerase chain reaction
(PCR) was positive with 91880 copies/mL. Bronchoscopy
did not reveal bronchial abnormalities. Bronchoalveolar
lavage (BAL) cytology was negative for viral inclusions, and
no organisms were isolated from cultures. CMV real-time
polymerase chain reaction (PCR) on BAL was positive (704
copies/mL).
5. Therapeutic Intervention
Acute CMV pneumonia in an immunocompetent host was
assumed, and antiviral therapy was started with ganciclovir
at a dose of 375mg (5mg/kg, patient weight 75 kg) intra-
venously at 12/12 h. We chose for ganciclovir based on the
clinical features and the result of CMV serology. We per-
formed a dilated eye exam which did not show any ocular
damage. After 48 hours, there was a significant clinical
improvement, with remission of fever. He was discharged on
the 13th day of hospitalization after finishing four days of
ganciclovir. Since we do not have oral formula of ganciclovir
in our country, the patient was medicated with oral val-
ganciclovir 900mg every 12 hours for 21 days, after which
complete resolution of symptoms was noted.
6. Follow-Up and Outcomes
'oracic-abdominal-pelvic CT, performed three months
after discharge, revealed resolution of the initial findings
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(Figure 3). Currently, the patient is healthy and without the
need for therapy.
7. Discussion
'e authors conducted a literature search, through the
PubMed platform, of articles on CMV infection in immu-
nocompetent individuals, using the words: cytomegalovirus,
pneumonia, and immunocompetent, until January 20, 2021.
'ey collected a total of 17 cases of CMV pneumonia (Table 2).
'e authors found that all cases occurred in developed
countries, which may reflect underdiagnosis in developing
countries. Ages range from 10 to 73 years, with an average of
40 years. Of the 17 cases, 11 patients were found to be male
and 6 were females.
To date, few cases of prolonged symptomatic infection
have been described, with the majority of studies reporting
cases of hepatitis and colitis [9]. In a retrospective study,
carried out by Faucher et al., in a total of 116 patients
hospitalized and followed up on an outpatient basis, it was
found that 99% had a fever with an average duration of 21
days [25]. Headache was described by 51%, while 46% had
myalgia and 36% had splenomegaly [25]. Pulmonary
symptoms were described in 8% of patients and neurological
symptoms in 1% [25]. Pulmonary involvement of CMV
disease is rare. Patients may present a dry cough or develop
severe interstitial pneumonia, making it necessary to per-
form a differential diagnosis with other viral infections as
influenza or adenovirus [2]. Although hypoxemia is fre-
quently present [2], our patient did not develop in the
disease course.
Regarding signs and symptoms, most of the patients
studied had fever, malaise, flu-like syndrome, dyspnea, and
cough. Some patients had involvement of other organ
systems with jaundice and abdominal pain. Only 2 of the 17
patients had associated comorbidities such as atrial













Hemoglobin (g/dL) 11.1 9.7 8.9 8.9 11,5 12
VCM (fL) 86.4 88.3 88.3 90.3 91,1 90,4
HCM (pg) 29.8 30.1 29.3 29.5 29,4 31,2
Prothrombin time (seg) 17.6 15.8 15.4 — 14,3 12,7
INR (ratio) 1.5 1.3 1.3 — 1,2 1,1
ALT/GPT (U/L) 199 153 249.9 190.6 120,4 68,8
AST/GOT (U/L) 207 95.9 192.2 79 56,4 35,4
GGT (U/L) — — 197.3 381.8 291,2 164,0
LDH (U/L) 692.0 749.0 885. 792 631,0 323,0
TBIL (mg/dL) — 0.9 0.8 0.7 0,7 0.5
ALP (U/L) — — 106. 143 121,0 105,0
CRP (mg/L) 22.3 46.5 55.4 26 6,8 —
Anti-CMV IgG (UA/mL) — — 21.4 — 75,7 71,3
Anti-CMV IgM (S/CO) — — 6.9 — 9,0 6,5
DNA (PCR) – cytomegalovirus
(copies/mL) — — 91880 — <250 <250
Figure 1: Chest X-ray performed on the 2nd trip to the ER: bilateral
perihilar reinforcement, erasure of both costophrenic sinuses, and
diffuse interstitial infiltrate are observed.
Figure 2: Chest CT with ground glass areas in the left and right
pulmonary lobes; bilateral pleural effusion.
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fibrillation, arterial hypertension, and obstructive sleep
apnea syndrome. Only one patient was a smoker.
Since there is no specific radiological pattern of pul-
monary involvement, the patient may present with an absent
or minimal initial pulmonary infiltrate or with diffuse in-
terstitial infiltrates [2]. Most of the patients analyzed had
diffuse interstitial infiltrates on chest teleradiography and
only one patient with localized disease, described by Gon-
çalves et al.
Laboratory diagnosis can be performed through sero-
logical tests or changes in biochemistry. Serology is based on
the elevation of the CMV IgM antibody titer or an increase
Table 2: Published clinical cases of CMV pneumonia in immunocompetent individuals.
Authors Year Country Age/sex Diagnostic method
Antiviral
therapy Outcome
Vogel [10] 1958 United States ofAmerica 10/M Histology None Died
Shoyama et al.
[11] 1969 Japan 63/F Histology None Died
Ii K et al. [12] 1972 Japan 73/M Histology None Died
Bäck et al. [13] 1977 Scandinavia 53/M Serology None Survived
Lipton et al. [14] 1981 United States ofAmerica 28/F Serology, histology, immunofluorescence None Died
Teixidor et al. [15] 1982 United States ofAmerica 21/F Histology None Died
Cohen et al. [16] 1985 United States ofAmerica 34/M Serology None Survived
Manian and
smith [17] 1993 Sweden 32/F Serology, culture Ganciclovir Survived
Halimi et al. [18] 1993 France 40/F Serology, culture, immunohistochemistry for CMVantigen in bronchoalveolar lavage Ganciclovir Survived
McCormak et al.




America 47/M Histology None Survived
Cunha et al. [21] 2008 United States ofAmerica 64/M Serology None Survived
Barclay et at. [22] 2011 UK 38/F Serology, PCR on blood Valganciclovir Survived
Grilli et al. [8] 2012 Italy 29/M Serology Valganciclovir Survived
Müller et al. [23] 2016 Germany 49/M Serology Valganciclovir Survived
Gonçalves et al.
[2] 2018 Portugal 29/M Serology Valganciclovir Survived
Waqas et al. [24] 2019 United States ofAmerica 38/M Serology, culture Valganciclovir Survived
Figure 3: Follow-up chest CT showing resolution of the ground glass areas and the bilateral pleural effusion.
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in the IgG antibody titer. In the clinical cases studied, the
diagnosis of CMV pneumonia was made by serology
established on IgM antibodies, cultures, or histology. In
patients who died, the diagnosis was established from the
findings of the histological examination during the autopsy.
In the clinical case presented, the diagnosis of infection
by CMVwas suspected after the exclusion of other etiologies
and confirmed by the elevated titers of IgM and IgG CMV
and by the detection of CMV DNA by PCR.
According to the Centers for Disease Control and
Prevention, there is no treatment established for CMV
infection in immunocompetent patients [2]. 'e literature
on current practices, although limited, suggests that an-
tiviral therapy directed with ganciclovir or valganciclovir is
suitable for severe infection in immunocompetent indi-
viduals [2]. Ganciclovir was patented in 1980 and approved
for the treatment of CMV infection in 1988 [24]. Val-
ganciclovir was approved for medical use in 2001. Seven of
the patients had CMV pneumonia before ganciclovir was
approved, in which five of them died, and two survived.
After the approval of ganciclovir, all the patients who
received antiviral therapy survived. In the cases where
authors described the administered dose, most of the pa-
tients received 900mg of valganciclovir twice a day. 'e
duration of treatment ranged from 4 to 21 days despite
significant clinical improvement in the first days. In this
presented patient, as soon as he started antiviral therapy
with ganciclovir, there was a significant clinical improve-
ment. All patients who were treated with ganciclovir or
valganciclovir showed good results and none of them re-
ported long-term sequelae.
With this clinical case, the authors highlight the im-
portance of considering CMV infection in evaluating pa-
tients with pneumonia, even in immunocompetent ones,
particularly in those with no clinical improvement with
antibiotics instituted for bacterial pneumonia, and when
other causes have been ruled out.
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